search
Back to results

Examining Pulmonary Rehabilitation on Discharged COPD Patients

Primary Purpose

Chronic Obstructive Pulmonary Disease (COPD)

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Pulmonary Rehabilitation (PR)
Usual Care
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring Acute Exacerbation of COPD (AECOPD), COPD, Emphysema, Chronic Bronchitis

Eligibility Criteria

50 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients admitted to the pulmonary ward for an AECOPD will be offered participation into this arm of the study.

Exclusion Criteria:

  • Acute cardiac injury during admission
  • Mobility issues
  • Residence outside the greater Edmonton area

Sites / Locations

  • University of Alberta Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Early Pulmonary Rehabilitation (EPR)

Late Pulmonary Rehabilitation (LPR)

Usual Care

Arm Description

Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.

Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.

Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.

Outcomes

Primary Outcome Measures

Change in Quality of Life - 1
Quality of Life - 1 will be assessed using the COPD Assessment tool.
Change in Vascular Function
Vascular function will be assessed using peripheral arterial tone (PAT)
Change in Central and Peripheral Arterial Stiffness (AS)
Arterial Stiffness will be assessed using pulse wave velocity measured from the carotid and femoral (central) and carotid and radial (peripheral) arteries.
Change in Quality of Life - 2
Quality of Life - 2 will be assessed using the St. George Respiratory Questionnaire.
Change in Quality of Life - 3
Quality of Life - 3 will be assessed using the COPD Self Efficacy Scale.

Secondary Outcome Measures

Change in Inflammatory marker (IL-6)
IL-6: is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine.
Change in Inflammatory marker (TNF-alpha)
TNF-alpha
Change in Inflammatory Marker (MMP-2)
MMP-2
Change in Inflammatory markers (CRP)
CRP: C-reactive protein is a non-specific serum marker of inflammation (range <8 is normal)
Change in Dyspnea (breathlessness)
Dyspnea (breathlessness) will be assessed using Modified Medical Research Council Dyspnea Scale (MMRC)

Full Information

First Posted
March 17, 2015
Last Updated
April 7, 2021
Sponsor
University of Alberta
Collaborators
University of Calgary
search

1. Study Identification

Unique Protocol Identification Number
NCT02426437
Brief Title
Examining Pulmonary Rehabilitation on Discharged COPD Patients
Official Title
How Does Early Rehabilitation Affect Patient-centred Health Outcomes and Cardiovascular Risk in COPD Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
February 2015 (Actual)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
December 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
Collaborators
University of Calgary

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease primarily caused by smoking. COPD creates a tremendous burden to the healthcare system, as disease exacerbations result in frequent, prolonged hospitalizations. While originally considered a disease specific to the lung, data has shown that COPD is associated with substantial cardiovascular (CV) morbidity and mortality. Exacerbations of COPD requiring hospitalization result in marked patient deterioration, and heightened CV risk. The cause of the increased CV risk with stable COPD, and the exaggerated CV risk during exacerbations of the disease are unknown; however, it may be due to chronic inflammation which is exacerbated with a flare-up of the disease, and/or chronic inactivity which is similarly worsened with bed-rest during a hospitalization. Despite the impact of COPD on healthcare, there are relatively few studies examining how COPD inpatient care impacts on patient outcomes, inflammation and CV risk. Disease management programs, such as pulmonary rehabilitation and patient self-management education, are part of guideline therapy for COPD; however, these are not regularly implemented following a hospitalization, and how these interventions affect patient outcomes, behavior, physical activity, inflammation and CV risk have not been well studied. The proposed long-term project will examine how early referral to chronic disease management programs after hospital discharge, affect patient outcomes. This study will provide invaluable information about outpatient management for a disease which has a tremendous impact on healthcare.
Detailed Description
Purpose: To examine the impact of early pulmonary rehabilitation (PR) following hospital discharge on QoL, pulmonary/CV outcomes and AECOPD hospitalizations. Rationale: In addition to typical improvements in QoL and exercise tolerance, studies have shown that PR increases self-efficacy and physical activity while reducing CV risk in stable COPD patients. Patients recently discharge from hospital following AECOPD represent the sickest patients with greatly reduced QoL, exercise tolerance, self-efficacy and physical activity. Exactly how these improve with PR following a hospitalization requires examination. Hypothesis: Patients who receive early PR will have improved QoL, pulmonary/CV outcomes and less hospitalizations for COPD in the 6 months following hospital discharge. PR will improve self efficacy, physical activity and QoL while reducing CV risk as compared to usual care. Study Design & Subject Recruitment: All patients admitted to the pulmonary ward for an AECOPD, will be offered participation into the study. Patients found to have an acute cardiac injury during admission, mobility issues or residence outside the greater Edmonton area will be excluded. Consenting patients will be subsequently randomized into one of three groups: early PR versus late PR versus usual care. Patients randomized to PR will be enrolled within 1 (Early PR; EPR) or 3 months (Late PR; LPR) of discharge into a PR program. Usual care patients will be followed-up by their most responsible physician as determined by the admitting team. The PR group will be enrolled in the Breathe Easy Program at the Center for Lung Health, and will proceed through the program in a typical fashion. All patients will be followed up 6 months after discharge and will be interviewed to assess disease status, management review and if there has been a history of recurrence or relapse of the AECOPD. Hospital admissions and length of stay data will be obtained through electronic medical records. Patient assessments will include: quality of life, 6min walk, dyspnea, self-efficacy, physical activity, pulse wave velocity, vascular function, systemic inflammation (TNFα, MMP-2, IL-6 and CRP) and FeNO. All data will be collected before, immediately after and 6 months after PR. The control group will have the same data collected at the same scheduled time. See above for descriptions of methods. Data Handling: Data will be entered onto a secure anonymized database. Data Analysis: The influence of PR on QoL, 6min walk, dyspnea, self-efficacy, physical activity, pulse wave velocity, vascular function, systemic inflammation and eNO will be analyzed using a multivariate mixed-model MANOVA with treatment (Early-PR vs. Late-PR vs. usual care) being a fixed between-group variable and time (pre, immediate post, 6months post) as a repeated variable. Sample size: Based on previous work, a sample size of 50 in each group (150 total) will be sufficient to detect a between-group differences in QoL, 6min walk, PWV, dyspnea and hospital readmission rates following PR (α=0.05, β=0.8). Based on the investigators recent work, this sample could detect a 10% difference in physical activity following PR (α=0.05, β=0.8). One hundred fifty patients will also allow for stratification of physiological and psychological responses with PR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
Acute Exacerbation of COPD (AECOPD), COPD, Emphysema, Chronic Bronchitis

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early Pulmonary Rehabilitation (EPR)
Arm Type
Other
Arm Description
Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
Arm Title
Late Pulmonary Rehabilitation (LPR)
Arm Type
Other
Arm Description
Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
Arm Title
Usual Care
Arm Type
Other
Arm Description
Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
Intervention Type
Other
Intervention Name(s)
Pulmonary Rehabilitation (PR)
Intervention Description
Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
Primary Outcome Measure Information:
Title
Change in Quality of Life - 1
Description
Quality of Life - 1 will be assessed using the COPD Assessment tool.
Time Frame
Change from Baseline Quality of Life - 1 at 8 weeks and 6 months
Title
Change in Vascular Function
Description
Vascular function will be assessed using peripheral arterial tone (PAT)
Time Frame
Change from Baseline Vascular Function at 8 weeks and 6 months
Title
Change in Central and Peripheral Arterial Stiffness (AS)
Description
Arterial Stiffness will be assessed using pulse wave velocity measured from the carotid and femoral (central) and carotid and radial (peripheral) arteries.
Time Frame
Change from Baseline Central and Peripheral Arterial Stiffness (AS) at 8 weeks and 6 months
Title
Change in Quality of Life - 2
Description
Quality of Life - 2 will be assessed using the St. George Respiratory Questionnaire.
Time Frame
Change from Baseline Quality of Life - 2 at 8 weeks and 6 months
Title
Change in Quality of Life - 3
Description
Quality of Life - 3 will be assessed using the COPD Self Efficacy Scale.
Time Frame
Change from Baseline Quality of Life - 3 at 8 weeks and 6 months
Secondary Outcome Measure Information:
Title
Change in Inflammatory marker (IL-6)
Description
IL-6: is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine.
Time Frame
Change from Baseline IL-6 at 8 weeks and 6 months
Title
Change in Inflammatory marker (TNF-alpha)
Description
TNF-alpha
Time Frame
Change from Baseline TNF-alpha at 8 weeks and 6 months
Title
Change in Inflammatory Marker (MMP-2)
Description
MMP-2
Time Frame
Change from Baseline MMP-2 at 8 weeks and 6 months
Title
Change in Inflammatory markers (CRP)
Description
CRP: C-reactive protein is a non-specific serum marker of inflammation (range <8 is normal)
Time Frame
Change from Baseline CRP at 8 weeks and 6 months
Title
Change in Dyspnea (breathlessness)
Description
Dyspnea (breathlessness) will be assessed using Modified Medical Research Council Dyspnea Scale (MMRC)
Time Frame
Change from Baseline Dyspnea at 8 weeks and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients admitted to the pulmonary ward for an AECOPD will be offered participation into this arm of the study. Exclusion Criteria: Acute cardiac injury during admission Mobility issues Residence outside the greater Edmonton area
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael K Stickland, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2B7
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Examining Pulmonary Rehabilitation on Discharged COPD Patients

We'll reach out to this number within 24 hrs